http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022041669-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2019-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef98ba2832b511ec7f2a671eefeac093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0b56f071037a3b10063030f294e25c9 |
| publicationDate | 2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022041669-A1 |
| titleOfInvention | Methods of treating or preventing conditions of dendritic and neural spine defects |
| abstract | Described are methods of treating or preventing dendritic spine loss in a subject. The methods include a step of administering to a subject having or at risk of having dendritic spine loss a pharmaceutical composition. In addition, pharmaceutical compositions are described comprises an agent selected from the group comprising a salt, solvate, or stereoisomer of a norrin protein or functional part thereof; a vector expressing the norrin protein or functional part thereof; or a combination thereof, and a pharmaceutically acceptable carrier. |
| priorityDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 170.